Clinical Nuclear Medicine

Skip Navigation LinksHome > April 2012 - Volume 37 - Issue 4 > Normal Uptake of 68Ga-DOTA-TOC by the Pancreas Uncinate Proc...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e3182485110
Original Articles

Normal Uptake of 68Ga-DOTA-TOC by the Pancreas Uncinate Process Mimicking Malignancy at Somatostatin Receptor PET

Jacobsson, Hans MD, PhD*,†; Larsson, Patricia MD*,†; Jonsson, Cathrine PhD; Jussing, Emma MPharm; Grybäck, Per MD, PhD*,†

Collapse Box


Purpose: To characterize a commonly occurring increased uptake by the uncinate process of the pancreas at PET/CT using 68Ga-DOTA-d-Phe1-Tyr3-octreotide (68Ga-DOTA-TOC). This tracer has replaced 111In pentetreotide (OctreoScan®) for somatostatin receptor scintigraphy at our laboratory.

Methods: Fifty of our first 74 PET/CT examinations with 68Ga-DOTA-TOC could be evaluated in retrospect. None of these patients had surgery or showed any pathology in the pancreas head at the concomitant CT.

Results: Thirty-five of the 50 examinations (70%) showed an uptake by the uncinate process sufficiently intense to be interpreted as pathologic and simulating a tumor. Mean SUVmax was 9.2. Mean SUVmean using an isoactivity cut-off of >75% and >50% was 7.8 and 6.0, respectively. Volume calculations of the uncinate process activity using these definitions gave 0.9 mL and 4.2 mL, respectively.

Conclusion: There is a frequent physiological uptake of 68Ga-DOTA-TOC by the pancreas uncinate process. This may be caused by an accumulation of pancreatic polypeptide-containing cells expressing somatostatin receptors. If there is a normal finding at concomitant diagnostic CT, this uptake should be regarded as physiological.

© 2012 Lippincott Williams & Wilkins, Inc.


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.